Anaptysbio (ANAB) Net Cash Flow Growth (1y) (2017 - 2026)
Anaptysbio (ANAB) Net Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Anaptysbio | 1.54 Bn | 1.26 Bn | - | 142.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 142.03% |
| Dec 31, 2025 | 287.39% |
| Sep 30, 2025 | -45.28% |
| Jun 30, 2025 | -399.78% |
| Mar 31, 2025 | -237.86% |
| Dec 31, 2024 | -808.39% |
| Sep 30, 2024 | 1,443.96% |
| Jun 30, 2024 | 130.54% |
| Mar 31, 2024 | -23.76% |
| Dec 31, 2023 | -24.22% |
| Sep 30, 2023 | 32.26% |
| Jun 30, 2023 | 37.33% |
| Mar 31, 2023 | 107.06% |
| Dec 31, 2022 | -91.99% |
| Sep 30, 2022 | -422.88% |
| Jun 30, 2022 | -296.88% |
| Mar 31, 2022 | -1,077.43% |
| Dec 31, 2021 | 285.79% |
| Sep 30, 2021 | 133.90% |
| Jun 30, 2021 | -13.87% |